GLAXOSMITHKLINE PLC - ADR (GSK)

Historical Holders from Q1 2014 to Q3 2025

Symbol
GSK on NYSE
Type / Class
Equity / ADR
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
2,101
Holdings value
$90,693
% of all portfolios
0%
Number of holders
5
Number of sells
1
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
As of 30 Sep 2025 GLAXOSMITHKLINE PLC - ADR (GSK) has 5 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,101 shares of the company stock as of 30 Sep 2025.

Institutional Holders of GLAXOSMITHKLINE PLC - ADR (GSK) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 2,101 $90,693 -$13,811 $43.16 5
2025 Q2 2,421 $92,983 -$31,852,663 $38.40 5
2025 Q1 824,648 $31,946,441 -$2,420,483 $38.74 6
2024 Q4 887,129 $30,003,023 -$6,268,690 $33.82 6
2024 Q3 1,088,929 $44,429,787 -$7,404,921 $40.88 7
2024 Q2 1,269,855 $48,887,021 -$472,713 $38.50 7
2024 Q1 1,282,058 $54,906,347 +$448,257 $42.87 9
2023 Q4 1,271,429 $47,119,589 -$923,394 $37.06 8
2023 Q3 1,295,426 $46,959,843 +$724,503 $36.25 9
2023 Q2 1,275,439 $45,456,543 -$504,373 $35.64 8
2023 Q1 1,289,591 $45,884,585 +$865,143 $35.58 9
2022 Q4 1,265,612 $44,473,979 -$39,580,166 $35.14 12
2022 Q3 2,672,147 $78,721,323 -$13,477,476,708 $29.43 30
2022 Q2 319,219,774 $13,900,172,460 -$335,770,041 $43.53 808
2022 Q1 330,038,084 $14,378,991,799 +$162,769,225 $43.56 896
2021 Q4 308,838,098 $13,617,786,241 +$198,337,774 $44.10 889
2021 Q3 323,226,938 $12,350,690,605 +$152,260,225 $38.21 767
2021 Q2 319,078,349 $12,705,963,590 -$351,544,014 $39.82 781
2021 Q1 316,397,805 $11,302,294,765 +$543,454,028 $35.69 757
2020 Q4 282,130,839 $10,385,357,290 +$199,792,176 $36.80 796
2020 Q3 297,399,112 $11,189,822,697 -$399,960,274 $37.64 808
2020 Q2 304,879,335 $12,435,647,404 -$288,969,437 $40.79 820
2020 Q1 311,501,203 $11,808,717,369 +$916,179,519 $37.89 796
2019 Q4 287,598,782 $13,511,415,726 +$320,332,416 $46.99 877
2019 Q3 281,445,024 $12,011,336,814 +$121,671,640 $42.68 789
2019 Q2 278,657,526 $11,152,427,420 -$13,000,558 $40.02 785
2019 Q1 280,230,407 $11,710,480,814 +$200,792,913 $41.79 827
2018 Q4 273,833,749 $10,467,518,909 +$78,202,591 $38.21 784
2018 Q3 272,226,534 $10,928,665,516 +$211,440,517 $40.17 776
2018 Q2 246,919,217 $9,947,792,896 -$271,064,081 $40.31 773
2018 Q1 275,386,419 $10,755,340,234 +$121,959,688 $39.07 766
2017 Q4 272,637,353 $9,670,376,435 +$1,018,117,019 $35.47 749
2017 Q3 242,360,134 $9,836,718,650 +$527,498,378 $40.60 732
2017 Q2 229,318,256 $9,881,828,420 +$323,644,299 $43.12 768
2017 Q1 221,048,119 $9,317,756,206 +$254,619,578 $42.16 775
2016 Q4 208,488,226 $8,027,519,507 +$51,431,248 $38.51 752
2016 Q3 206,915,393 $8,924,777,331 -$126,362,239 $43.13 723
2016 Q2 210,001,685 $9,104,951,943 +$231,286,578 $43.34 728
2016 Q1 204,797,543 $8,334,355,321 -$334,382,915 $40.55 707
2015 Q4 214,971,066 $8,672,738,505 -$153,787,754 $40.35 705
2015 Q3 217,477,264 $8,371,585,657 -$453,104,694 $38.45 689
2015 Q2 230,268,780 $9,590,935,017 -$824,396,346 $41.65 706
2015 Q1 249,750,914 $11,526,753,874 -$100,820,332 $46.15 722
2014 Q4 253,598,053 $10,835,627,801 -$557,317,025 $42.74 711
2014 Q3 264,943,921 $12,179,428,769 -$647,010,612 $45.97 691
2014 Q2 277,950,560 $14,864,056,073 +$860,594,396 $53.48 710
2014 Q1 261,888,533 $13,992,393,373 -$160,771,004 $53.43 703